PD-1 mAB cemiplimab approved for cutaneous squamous cell carcinoma

Non-Sponsored Content

PD-1 inhibitor cemiplimab FDA approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC)

By: News Feed | Last updated: 3rd October 2018 | In: ImmunoOncology, Immunotherapy, Melanoma & Skin Cancer, Oncology, US FDA Onc\Haem Approvals

Article Keywords

cemiplimab, CSCC, FDA, Libtayo, PD-1, Regeneron, REGN2810, squamous cell skin cancer

On September 28, 2018, the FDA approved programmed death 1 (PD-1) immune-checkpoint inhibitor cemiplimab-rwlc (Libtayo®, Regeneron) for use in patients with metastatic cutaneous squamous cell carcinoma (CSCC) and patients with locally advanced CSCC unamenable for curative surgery or curative radiation.

Studies R2810-ONC-1423 and R2810-ONC-1540

The FDA approval was based on the objective response rates (ORR) with cemiplimab-rwlc in patients with advanced CSCC participating in two clinical trials.

The first study was an open-label, multicentre, dose-finding study (R2810-ONC-1423, NCT02383212) with expansion cohorts which investigated cemiplimab-rwlc in patients with various advanced solid tumours.

The second study was an open-label, multi-centre, non-randomised, multicohort study (R2810-ONC-1540, NCT02760498) which investigated cemiplimab-rwlc metastatic or locally advanced CSCC patients unamenable for surgery or radiation and regardless of prior therapies received.

The ORR (by RECIST 1.1) for patients with metastatic CSCC was assessed by an independent review committee (IRC). Patients with locally advanced CSCC underwent a composite response assessment of clinical response criteria by digital photography and RECIST 1.1.

The two studies included 108 patients with advanced CSCC, including 75 (69%) with metastatic CSCC and 33 (31%) with locally advanced CSCC. The ORR by IRC was 47% (95% CI, 38-57), made up of 4% complete responses (CR) and 44% partial responses (PR).

The ORR for patients with metastatic CSCC was 47% (95% CI, 35-59) and 49% (95% CI, 31-67) for those with locally advanced disease. At the time of data cut-off, the median response duration was not yet reached (range: 1.0 to 15.2+ months), with 61% of the responses lasting six months or longer. The ORR and durability results were consistent across CSCC subtypes. In patients with locally advanced CSCC, clinical observations as per photographic data matched the radiographic responses.

Safety

The safety data included 534 patients treated in both cemiplimab-rwlc trials. Serious adverse reactions included immune-related adverse events (irAEs) such as pneumonitis, hepatitis, colitis, adrenal insufficiency, hypo- and hyperthyroidism, diabetes mellitus and nephritis as well as infusion reactions. Common adverse reactions were fatigue, rash and diarrhoea.

Prescribing information Libtayo.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Second-line treatment of gastric cancer or cancer of the gastroesophegeal junction: a case study of ramucirumab in Hong Kong

Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients

Calaspargase pegol-mknl (Asparlas®) FDA approved in paediatric and young adult acute lymphoblastic leukaemia (ALL) patients

Fully resorbable synthetic matrix offers improved safety for breast cancer patients undergoing immediate breast reconstruction

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

krishnacreations / 123RF Stock Photo

FDA granted accelerated approval to blinatumomab for the treatment of adult and paediatric patients with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

Trackbacks & Pingbacks

Approved Immune-Checkpoint Inhibitors and Immunotherapies says:

8th November 2018 at 10:52 PM

[…] Cemiplimab, an anti PD-1 monoclonal antibody, received the first indication by the U.S. FDA in September 2018 and is marketed as Libtayo®. Doctors can prescribe cemiplimab (Libtayo®) for the following disease:7Prescribing information cemiplimab (Libtayo®), revised: 09/2018 […]

Log in to Reply

Want to join the discussion?
Feel free to contribute!